Vanguard Group Inc. Sells 380,582 Shares of Gilead Sciences, Inc. $GILD

Vanguard Group Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,983,644 shares of the biopharmaceutical company’s stock after selling 380,582 shares during the period. Vanguard Group Inc. owned 0.10% of Gilead Sciences worth $13,207,184,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Eagle Rock Investment Company LLC increased its holdings in shares of Gilead Sciences by 2.8% during the third quarter. Eagle Rock Investment Company LLC now owns 9,544 shares of the biopharmaceutical company’s stock worth $1,059,000 after buying an additional 260 shares in the last quarter. Fifth Third Bancorp grew its position in Gilead Sciences by 3.9% during the 3rd quarter. Fifth Third Bancorp now owns 393,565 shares of the biopharmaceutical company’s stock worth $43,686,000 after acquiring an additional 14,642 shares during the last quarter. Pallas Capital Advisors LLC grew its position in Gilead Sciences by 1.6% during the 3rd quarter. Pallas Capital Advisors LLC now owns 8,846 shares of the biopharmaceutical company’s stock worth $982,000 after acquiring an additional 137 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in Gilead Sciences by 3.9% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 435,008 shares of the biopharmaceutical company’s stock worth $48,286,000 after purchasing an additional 16,160 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Gilead Sciences by 1.2% in the third quarter. PNC Financial Services Group Inc. now owns 420,970 shares of the biopharmaceutical company’s stock valued at $46,728,000 after purchasing an additional 4,834 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. The trade was a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the insider owned 103,221 shares in the company, valued at $12,831,402.51. The trade was a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 288,891 shares of company stock worth $40,303,946. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Scotiabank boosted their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Leerink Partners increased their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $152.50.

Gilead Sciences Trading Up 2.1%

GILD opened at $154.98 on Monday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a fifty day moving average of $130.27 and a 200-day moving average of $122.38. The stock has a market cap of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.